Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
OVAS's Cash to Debt is ranked higher than
78% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. OVAS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OVAS' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity to Asset 0.92
OVAS's Equity to Asset is ranked higher than
88% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OVAS: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
OVAS' s Equity to Asset Range Over the Past 10 Years
Min: 0.89  Med: 0.93 Max: 0.96
Current: 0.92
0.89
0.96
Interest Coverage No Debt
OVAS's Interest Coverage is ranked higher than
69% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OVAS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OVAS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: 12.32
M-Score: 6.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -13702.29
OVAS's Operating margin (%) is ranked lower than
93% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. OVAS: -13702.29 )
Ranked among companies with meaningful Operating margin (%) only.
OVAS' s Operating margin (%) Range Over the Past 10 Years
Min: -25992.42  Med: -25992.42 Max: -13702.29
Current: -13702.29
-25992.42
-13702.29
Net-margin (%) -13906.35
OVAS's Net-margin (%) is ranked lower than
94% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. OVAS: -13906.35 )
Ranked among companies with meaningful Net-margin (%) only.
OVAS' s Net-margin (%) Range Over the Past 10 Years
Min: -26432.85  Med: -26432.85 Max: -13906.35
Current: -13906.35
-26432.85
-13906.35
ROE (%) -57.85
OVAS's ROE (%) is ranked lower than
65% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. OVAS: -57.85 )
Ranked among companies with meaningful ROE (%) only.
OVAS' s ROE (%) Range Over the Past 10 Years
Min: -102.08  Med: -87.86 Max: -57.85
Current: -57.85
-102.08
-57.85
ROA (%) -53.52
OVAS's ROA (%) is ranked lower than
71% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. OVAS: -53.52 )
Ranked among companies with meaningful ROA (%) only.
OVAS' s ROA (%) Range Over the Past 10 Years
Min: -87.56  Med: -72.27 Max: -53.52
Current: -53.52
-87.56
-53.52
ROC (Joel Greenblatt) (%) -1077.44
OVAS's ROC (Joel Greenblatt) (%) is ranked lower than
62% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. OVAS: -1077.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OVAS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3579.1  Med: -2909.44 Max: -1077.44
Current: -1077.44
-3579.1
-1077.44
» OVAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2015

OVAS Guru Trades in Q1 2015

Jim Simons Sold Out
» More
Q4 2015

OVAS Guru Trades in Q4 2015

Jim Simons 97,435 sh (New)
» More
Q1 2016

OVAS Guru Trades in Q1 2016

Jim Simons Sold Out
» More
Q2 2016

OVAS Guru Trades in Q2 2016

Paul Tudor Jones 42,925 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with OVAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:TYMI, NAS:PTI, NAS:PRTK, NAS:MNKD, NAS:ESPR, OTCPK:GNIXF, NAS:SYRS, NAS:CLSD, NAS:SQNM, NAS:FOMX, NAS:IMMU, OTCPK:SPHDF, NAS:BSTC, NAS:EDGE, NAS:CRIS, NAS:CRBP, NAS:SELB, NAS:CXRX, NAS:RXDX, NAS:PETX » details
Traded in other countries:3OS.Germany,
OvaScience Inc is a life science company engaged in discovery, development, and commercialization of new fertility treatments. Its patented technology is based on egg precursor cells found in the outer layer of a woman's own ovaries.

OvaScience, Inc. was established in 2011 & is based in Cambridge, Massachusetts. The Company is a life science company developing proprietary products to improve the treatment of female infertility based on recent scientific discoveries about the existence of egg precursor cells. The Company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011.

Ratios

vs
industry
vs
history
P/B 2.04
OVAS's P/B is ranked higher than
76% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. OVAS: 2.04 )
Ranked among companies with meaningful P/B only.
OVAS' s P/B Range Over the Past 10 Years
Min: 1.1  Med: 2.25 Max: 7.51
Current: 2.04
1.1
7.51
P/S 420.00
OVAS's P/S is ranked lower than
93% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. OVAS: 420.00 )
Ranked among companies with meaningful P/S only.
OVAS' s P/S Range Over the Past 10 Years
Min: 252  Med: 934.09 Max: 46970
Current: 420
252
46970
Current Ratio 13.98
OVAS's Current Ratio is ranked higher than
85% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. OVAS: 13.98 )
Ranked among companies with meaningful Current Ratio only.
OVAS' s Current Ratio Range Over the Past 10 Years
Min: 6.08  Med: 14.73 Max: 30.5
Current: 13.98
6.08
30.5
Quick Ratio 13.98
OVAS's Quick Ratio is ranked higher than
86% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. OVAS: 13.98 )
Ranked among companies with meaningful Quick Ratio only.
OVAS' s Quick Ratio Range Over the Past 10 Years
Min: 6.08  Med: 14.73 Max: 30.5
Current: 13.98
6.08
30.5
Days Payable 199.71
OVAS's Days Payable is ranked higher than
83% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. OVAS: 199.71 )
Ranked among companies with meaningful Days Payable only.
OVAS' s Days Payable Range Over the Past 10 Years
Min: 199.71  Med: 544.01 Max: 544.01
Current: 199.71
199.71
544.01

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.21
OVAS's Price/Net Cash is ranked higher than
87% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 6.18 vs. OVAS: 2.21 )
Ranked among companies with meaningful Price/Net Cash only.
OVAS' s Price/Net Cash Range Over the Past 10 Years
Min: 1.37  Med: 3.58 Max: 21.26
Current: 2.21
1.37
21.26
Price/Net Current Asset Value 2.16
OVAS's Price/Net Current Asset Value is ranked higher than
86% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. OVAS: 2.16 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OVAS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.34  Med: 3.51 Max: 20.66
Current: 2.16
1.34
20.66
Price/Tangible Book 2.04
OVAS's Price/Tangible Book is ranked higher than
82% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. OVAS: 2.04 )
Ranked among companies with meaningful Price/Tangible Book only.
OVAS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.26  Med: 3.44 Max: 19.24
Current: 2.04
1.26
19.24
Price/Median PS Value 0.45
OVAS's Price/Median PS Value is ranked higher than
85% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. OVAS: 0.45 )
Ranked among companies with meaningful Price/Median PS Value only.
OVAS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.28  Med: 1.39 Max: 37.34
Current: 0.45
0.28
37.34
Earnings Yield (Greenblatt) (%) -51.50
OVAS's Earnings Yield (Greenblatt) (%) is ranked lower than
87% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. OVAS: -51.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OVAS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7212.99  Med: 0 Max: 9387.28
Current: -51.5
-7212.99
9387.28

More Statistics

Revenue (TTM) (Mil) $0.57
EPS (TTM) $ -2.83
Beta4.81
Short Percentage of Float31.16%
52-Week Range $4.53 - 18.87
Shares Outstanding (Mil)35.56

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 11 54 144
EPS ($) -2.42 -1.83 -1.39 -0.39
EPS w/o NRI ($) -2.42 -1.83 -1.39 -0.39
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for OVAS

Headlines

Articles On GuruFocus.com
Oppenheimer Weighs in on Biotech Stocks: Opko Health, OvaScience Inc May 13 2015 
Upcoming Events in Biotechnology: OVAS, ICPT, TTPH, RCPT Apr 07 2015 
Analyst Remains Bullish While OvaScience Posts Losses in Q4 Report Mar 18 2015 
OvaScience’s Fertility Treatment Shows Promise Jan 20 2015 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 

More From Other Websites
OvaScience (OVAS) Shares March Higher, Can It Continue? Sep 20 2016
ETF’s with exposure to OvaScience, Inc. : September 15, 2016 Sep 15 2016
OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Sep 14 2016
OVASCIENCE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Sep 06 2016
OvaScience Announces Executive Management Changes and Appointments to Further Drive Company’s... Sep 06 2016
OvaScience to Present at Upcoming Investor Conferences in September Aug 31 2016
OvaScience’s AUGMENT Treatment Commercially Available in Japan Through Partnership with IVF JAPAN... Aug 29 2016
OvaScience’s AUGMENT Treatment Commercially Available in Japan Through Partnership with IVF JAPAN... Aug 29 2016
ETF’s with exposure to OvaScience, Inc. : August 26, 2016 Aug 26 2016
ETF’s with exposure to OvaScience, Inc. : August 15, 2016 Aug 15 2016
Edited Transcript of OVAS earnings conference call or presentation 4-Aug-16 8:30pm GMT Aug 15 2016
OVASCIENCE, INC. Financials Aug 12 2016
OvaScience, Inc. :OVAS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Can The Uptrend Continue for OvaScience (OVAS)? Aug 11 2016
OvaScience reports 2Q loss Aug 04 2016
OvaScience reports 2Q loss Aug 04 2016
OVASCIENCE, INC. Files SEC form 10-Q, Quarterly Report Aug 04 2016
OVASCIENCE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2016
OvaScience Reports Second Quarter 2016 Financial Results Aug 04 2016
Q2 2016 OvaScience Inc Earnings Release - After Market Close Aug 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)